Stocks · News reference
Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maintain marketing authorizations for YCANTH in Israel. Verrica will manufacture YCANTH and provide commercial supply to
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Verrica Pharmaceuticals (NASDAQ:VRCA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial
Filed: 2026-08-06 AccNo: 0001193125-26-338273 Size: 304 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 292 percent decrease over earnings of $0.25 per